Sinomenine can prolong high-risk corneal graft survival in a rat model

Author:

Wang Ying1,Ma Dongli2,Jie Ying2,Wu Yuying2,Pan Zhiqiang3

Affiliation:

1. Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China

2. Beijing Tongren Eye Centre, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Science Key Laboratory #1 Dongjiao Minxiang, Dongcheng District, Beijing 100730, People’s Republic of China

3. Beijing Tongren Eye Centre, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Science Key Laboratory #1 Dongjiao Minxiang, Dongcheng District, Beijing 100730, People’s Republic of China.

Abstract

Aims: To study the role of sinomenine (SIN) in prolonging high-risk corneal graft survival in rats. Methods: All recipients were randomly assigned to SIN, cyclosporine A (CsA), SIN plus CsA and control groups. IL-2, IL-10, Fas–Fas ligand and CD4+CD25+FoxP3+ T cells in peripheral blood were detected. In addition, rat corneal grafts’ survival times were recorded. Results: Survival time was 15.88 ± 5.87 days in the SIN group, 17.67 ± 5.43 days in the CsA group and 20.75 ± 4.77 days in the drug combination group, which were longer survival times than those in the control group (p < 0.05). Compared with the SIN and CsA groups, levels of CD4+CD25+FoxP3+ lymphocytes in the control group were decreased (p < 0.05) and were increased in the cotreated group (p < 0.05). IL-2 levels in the SIN-only and CsA-only groups were lower than those in the control group (p < 0.05) and higher than those in the cotreated group (p < 0.05); however, the results for IL-10 were different. The expressions of Fas and Fas ligand were least in the control group. Conclusion: SIN could prolong allograft survival and might have potential clinical usage.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3